Corpus Intelligence IC Memo — GOOD SHEPHERD SPECIALTY HOSPITAL 2026-04-26 09:35 UTC
IC Memo — GOOD SHEPHERD SPECIALTY HOSPITAL
Investment Committee Memorandum | PA | 32 beds | Grade D | EBITDA uplift $814K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

GOOD SHEPHERD SPECIALTY HOSPITAL

CCN 392033 | LEHIGH, PA | 32 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

GOOD SHEPHERD SPECIALTY HOSPITAL is a 32-bed under-performing / distressed in LEHIGH, PA with $11.0M in net patient revenue and a -61.1% operating margin. The hospital serves a payer mix of 52.7% Medicare, 0.2% Medicaid, and 47.1% commercial.

Thesis: Turnaround. Our ML models identify $814K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -61.1% to -53.7% (+740bps).

Net Revenue HCRIS$11.0M
Current EBITDA COMPUTED$-6.7M
Operating Margin COMPUTED-61.1%
Occupancy HCRIS48.1%
Revenue / Bed COMPUTED$343K
Net-to-Gross HCRIS27.1%
Distress Probability ML49.4%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
70
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -61.1% places it below the state median. Among 70 size-comparable peers (16-64 beds), the median margin is -0.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (16-64), prioritizing same-state peers. 70 hospitals in the comp set.

HospitalStateBedsRevenueMargin
GOOD SHEPHERD SPECIALTY HOSPIT (Target)PA32$11.0M-61.1%
OSS ORTHOPAEDIC HOSPITALPA30$149.4M-5.0%
WELLSPAN SURGERY AND REHAB HOSPA25$120.2M2.8%
UPMC LITITZPA36$114.5M14.2%
MINERS MEMORIAL MEDICAL CENTERPA49$107.7M12.4%
LVH-COORDINATED ALLENTOWNPA20$89.6M2.3%
CHARLES COLE MEMORIAL HOSPITALPA25$88.1M-9.0%
ST LUKES HOSPITAL-CARBON CAMPUPA52$86.4M8.1%
POCONO MEDICAL CENTER DICKSON PA40$85.9M0.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $814K (740bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$231K+210bp18mo
Denial Rate Reduction12.0%6.5%$220K+200bp12mo
Cost to Collect4.5%2.5%$220K+200bp12mo
A/R Days Reduction5200.0%3800.0%$134K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+9bp6mo

5. EBITDA Bridge

Net Collection Rate
$231K
Denial Rate Reduction
$220K
Cost to Collect
$220K
A/R Days Reduction
$134K
Clean Claim Rate
$10K
Total EBITDA Uplift$814K
Current EBITDA$-6.7M
+ RCM Uplift+$814K
Pro Forma EBITDA$-5.9M
Current Margin-61.1%
Pro Forma Margin-53.7%
WC Released (1x)$422K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-10.3M$-36.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-10.3M$-43.2M0.00x-100.0%
Bull Case9.0x11.0x$-9.3M$-43.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-9.3M$-50.6M0.00x-100.0%
Bear Case11.0x10.0x$-11.4M$-36.9M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-11.4M$-44.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 70 hospitals with 16-64 beds
  • Same-state prioritization (n=71)
  • Comp margins: P25=-15.4% / P50=-0.5% / P75=8.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.